TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved pritelivir (Hovilpri) for herpes simplex virus mucocutaneous lesions in immunocompromised patients whose infections have not responded to other treatments. In the phase III PRIOH-1 trial, 63% of patients receiving pritelivir had all lesions healed by day 28, compared with 34% receiving an investigator-selected alternative.
The U.S. Food and Drug Administration approved pritelivir, sold as Hovilpri, for herpes simplex virus (HSV) mucocutaneous lesions in immunocompromised patients whose infections have not responded to other treatments. The oral drug offers a new treatment option for patients with difficult-to-treat HSV, including infections resistant to commonly used antiviral medicines.
Pritelivir is an oral helicase-primase inhibitor intended to treat lesions caused by HSV-1 or HSV-2. According to the report by MedPage Today, its approval covers immunocompromised patients with HSV-related mucocutaneous lesions who have not responded to other treatments. The source describes the drug as active against strains resistant to nucleoside analogue- and foscarnet-based treatments.
The FDA approval was based on the open-label, phase III PRIOH-1 trial, which enrolled 101 immunocompromised patients with mucocutaneous HSV infections that had not responded to acyclovir, valacyclovir or famciclovir. Participants received once-daily pritelivir or a treatment chosen by investigators: foscarnet, cidofovir or imiquimod.
By day 28, 63% of patients taking 100 mg of pritelivir once daily had all lesions healed, meeting the trial’s primary efficacy endpoint. The corresponding result was 34% among patients receiving an investigator-selected treatment. The most commonly reported adverse reaction among pritelivir recipients was headache, according to the report.
A New Option for Resistant HSV
The approval addresses a treatment gap for people with weakened immune systems whose HSV lesions persist despite standard antiviral medicines. Immunocompromised patients may include people with hematologic cancers or disorders, recipients of stem-cell or solid-organ transplants, people with HIV, and patients with autoimmune or inflammatory diseases. The PRIOH-1 results provide a clinical basis for offering pritelivir to this defined group, rather than only relying on the alternatives studied in the trial.
The difference in the trial’s day-28 healing results—63% with pritelivir versus 34% with investigator-selected therapy—indicates a potential benefit in this population. It does not establish that every patient will respond, or that pritelivir is appropriate for people outside the approved group. The findings also matter because HSV infections are incurable: treatment aims to manage active disease and heal lesions, not eliminate the virus.
herpes simplex virus treatment oral medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How PRIOH-1 Tested Pritelivir
HSV infections can cause mucocutaneous lesions, including on the lips, nostrils, eyes and genitals. The source report says these lesions are a particular concern for people with compromised immune systems. PRIOH-1 focused on patients whose infection had not responded to three established antivirals—acyclovir, valacyclovir or famciclovir—so its results apply to a more treatment-resistant group, not to all people with herpes.
The trial was open-label, meaning treatment assignment was not blinded to participants and investigators. Its comparison group did not receive a single uniform drug: investigators selected foscarnet, cidofovir or imiquimod. Participants also had varied underlying conditions, including malignancies, transplantation, HIV and autoimmune or inflammatory disease. These details help define who was studied and how the reported results were generated.
““Achieving rapid lesion healing while maintaining tolerability is essential.””
— Cynthia Wat, MD, chief medical officer of Aicuris
resistant herpes lesions medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Questions About Use and Outcomes
The available report does not provide the full FDA prescribing information, including detailed dosing instructions, warnings, interactions or monitoring requirements. It also does not give a breakdown of healing outcomes by the participants’ underlying condition, HSV type, or resistance pattern. Those details may help clinicians understand how results apply across the varied immunocompromised population studied.
The trial’s open-label design and its investigator-selected comparison treatments are relevant when interpreting the results. The reported figures describe the share of participants with all lesions healed by day 28; they do not establish how quickly individual patients healed, how long the benefit lasted, or whether the results extend to patients whose HSV responds to existing medicines. Longer-term outcomes and the frequency of adverse reactions beyond the most commonly reported headache are not detailed in the source material.
immunocompromised herpes treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Prescribing Details After Approval
With FDA approval announced, the next practical step is for clinicians and patients to consult the official prescribing information for the authorized dose, safety guidance and eligibility details. The source report does not state when Hovilpri will be available, its price, or whether additional post-approval studies or monitoring requirements have been set.
Further reporting and published trial details may clarify how pritelivir performs across different causes of immunosuppression, how durable lesion healing is, and how its risks compare with the alternatives. For now, the confirmed development is an approval for a specific group with treatment-refractory HSV lesions, not a general treatment for all HSV infections.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who is pritelivir approved to treat?
The approval covers immunocompromised patients with HSV-related mucocutaneous lesions whose infections have not responded to other treatments, according to the source report.
How did pritelivir perform in the trial?
In the phase III PRIOH-1 trial, 63% of patients receiving 100 mg once daily had all lesions healed by day 28, compared with 34% in the group given an investigator-selected treatment.
What treatments were used for comparison?
Investigators selected foscarnet, cidofovir or imiquimod for the comparison group. The study enrolled patients whose infections had not responded to acyclovir, valacyclovir or famciclovir.
What side effect was reported most often?
Headache was the most common adverse reaction reported among patients who received pritelivir in the source material. The full prescribing information should be consulted for complete safety details.
Does pritelivir cure herpes?
No. HSV infections are incurable; the approval is for treating mucocutaneous lesions in a specified patient group. The report does not say that pritelivir eliminates HSV from the body.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
